Ptc Therapeutics (PTCT) Liabilities and Shareholders Equity (2012 - 2026)

Ptc Therapeutics' Liabilities and Shareholders Equity history runs 15 years deep, the most recent figure standing at $3.3 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity rose 23.4% year-over-year to $3.3 billion; the TTM figure through Jun 2026 stood at $11.7 billion (up 31.97% YoY), while the FY2025 annual figure was $2.9 billion, up 70.01% from the prior year.
• Liabilities and Shareholders Equity for Q2 2026 stood at $3.3 billion, up from $2.9 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $3.3 billion in Q2 2026, with the low at $1.3 billion in Q3 2023.
• The 5-year median for Liabilities and Shareholders Equity is $1.8 billion (2022), against an average of $2.1 billion.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity decreased 25.83% in 2023, then soared 70.01% in 2025.
• Ptc Therapeutics' Liabilities and Shareholders Equity stood at $1.7 billion in 2022, then gained by 11.14% to $1.9 billion in 2023, then dropped by 10.06% to $1.7 billion in 2024, then jumped by 70.01% to $2.9 billion in 2025, then climbed by 12.13% to $3.3 billion in 2026.
• Business Quant data shows PTCT's Liabilities and Shareholders Equity at $3.3 billion in Q2 2026, $2.9 billion in Q1 2026, and $2.9 billion in Q4 2025.